Advances in research on malignant transformation of endometriosis-associated ovarian cancer

被引:0
作者
Chen, Fang [1 ]
Zhu, Mengying [2 ]
Li, Wenjuan [1 ]
机构
[1] Peoples Hosp Liaoning Prov, Dept Gynecol, Shenyang, Peoples R China
[2] Liaoning Univ Tradit Chinese Med, Shenyang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
endometriosis; endometriosis-associated ovarian carcinoma; malignant transformation; ovarian clear cell carcinoma; ovarian endometrioid carcinoma; CLEAR-CELL CARCINOMA; EPITHELIAL OVARIAN; FALLOPIAN-TUBE; DOSE-DENSE; CHEMOTHERAPY; PACLITAXEL; MUTATIONS; METHYLATION; MECHANISMS; EXPRESSION;
D O I
10.3389/fonc.2024.1475231
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Endometriosis (EMs) is a prevalent chronic gynecological condition that depends on estrogen, marked by the presence of active endometrial tissue (glands and stroma) outside the uterus. Although pathologically benign, it exhibits biological behaviors such as invasion and metastasis akin to malignant tumors. Endometriosis-associated ovarian carcinoma (EAOC), arising from malignant transformation of EMs, poses significant clinical challenges. However, the mechanisms underlying EAOC pathogenesis remain incompletely understood, with a lack of reliable biomarkers for early diagnosis and personalized treatment strategies. Considering the significant number of EMs patients and the extended period during which malignant transformation can occur, EAOC deserves significant attention. Current research both domestically and internationally indicates that the pathogenesis of EAOC is complex, involving genetic mutations, immune microenvironment, oxidative stress, epigenetic changes, and related areas. This review summarizes the mechanisms underlying the development of EAOC.
引用
收藏
页数:9
相关论文
共 82 条
  • [1] How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer
    Afify, Said M.
    Oo, Aung Ko Ko
    Hassan, Ghmkin
    Seno, Akimasa
    Seno, Masaharu
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (06) : 605 - 619
  • [2] Targeting the DNA replication stress phenotype of KRAS mutant cancer cells
    Al Zubaidi, Tara
    Gehrisch, O. H. Fiete
    Genois, Marie-Michelle
    Liu, Qi
    Lu, Shan
    Kung, Jong
    Xie, Yunhe
    Schuemann, Jan
    Lu, Hsiao-Ming
    Hata, Aaron N.
    Zou, Lee
    Borgmann, Kerstin
    Willers, Henning
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [3] The impact of reproductive hormones on T cell immunity; normal and assisted reproductive cycles
    Alanazi, Hallah
    Zhang, Yuan
    Fatunbi, Joy
    Luu, Than
    Kwak-Kim, Joanne
    [J]. JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2024, 165
  • [4] Maximizing the delivery of intraperitoneal therapy while minimizing drug toxicity and maintaining quality of life
    Alberts, David S.
    Delforge, Ardie
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (06) : S8 - S17
  • [5] BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
    Alsop, Kathryn
    Fereday, Sian
    Meldrum, Cliff
    deFazio, Anna
    Emmanuel, Catherine
    George, Joshy
    Dobrovic, Alexander
    Birrer, Michael J.
    Webb, Penelope M.
    Stewart, Colin
    Friedlander, Michael
    Fox, Stephen
    Bowtell, David
    Mitchell, Gillian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) : 2654 - 2663
  • [6] Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer
    Barlin, Joyce N.
    Dao, Fanny
    Zgheib, Nadim Bou
    Ferguson, Sarah E.
    Sabbatini, Paul J.
    Hensley, Martee L.
    Bell-McGuinn, Katherine M.
    Konner, Jason
    Tew, William P.
    Aghajanian, Carol
    Chi, Dennis S.
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 125 (03) : 621 - 624
  • [7] Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis
    Barreta, Amilcar
    Sarian, Luis Otavio
    Ferracini, Amanda Canato
    Eloy Costa, Larissa Bastos
    Mazzola, Priscila Gava
    Andrade, Liliana de Angelo
    Derchain, Sophie
    [J]. HUMAN PATHOLOGY, 2019, 85 : 72 - 81
  • [8] ESHRE guideline: endometriosis
    Becker, Christian M.
    Bokor, Attila
    Heikinheimo, Oskari
    Horne, Andrew
    Jansen, Femke
    Kiesel, Ludwig
    King, Kathleen
    Kvaskoff, Marina
    Nap, Annemiek
    Petersen, Katrine
    Saridogan, Ertan
    Tomassetti, Carla
    van Hanegem, Nehalennia
    Vulliemoz, Nicolas
    Vermeulen, Nathalie
    [J]. HUMAN REPRODUCTION OPEN, 2022, 2022 (02)
  • [9] A systematic review of epigenetics of endometriosis
    Bedrick, Bronwyn S.
    Courtright, Laura
    Zhang, Jiahui
    Snow, Morgan
    Amendola, Isabela Landsteiner Sampaio
    Nylander, Elisabeth
    Cayton-Vaught, Kamaria
    Segars, James
    Singh, Bhuchitra
    [J]. F&S REVIEWS, 2024, 5 (01):
  • [10] Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
    Bitler, Benjamin G.
    Aird, Katherine M.
    Garipov, Azat
    Li, Hua
    Amatangelo, Michael
    Kossenkov, Andrew V.
    Schultz, David C.
    Liu, Qin
    Shih, Ie-Ming
    Conejo-Garcia, Jose R.
    Speicher, David W.
    Zhang, Rugang
    [J]. NATURE MEDICINE, 2015, 21 (03) : 231 - +